Oral Abrocitinib for Treatment of Refractory Alopecia Areata: A Retrospective Study

This retrospective study assessed the efficacy and tolerability of oral abrocitinib, a selective JAK1 inhibitor, in treating refractory alopecia areata (AA) in 13 patients. The study found that abrocitinib significantly reduced the Severity of Alopecia Score (SALT) from 74.62 to 42.54, with 46.15% achieving a SALT score ≤ 20, 53.85% achieving SALT50, and 38.46% achieving SALT75. Among patients with eyebrow/eyelash involvement, 5 experienced regrowth. Adverse effects were mild, including folliculitis and nausea. The study suggests abrocitinib may be effective for AA without atopic dermatitis, but a larger long-term study is needed to confirm these findings.